Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M248,567Revenue $M49,242Net Margin (%)23.2Z-Score5.0
Enterprise Value $M255,685EPS $1.7Operating Margin %34.3F-Score8
P/E(ttm))20.8Cash Flow Per Share $0Pre-tax Margin (%)31.0Higher ROA y-yY
Price/Book10.910-y EBITDA Growth Rate %0Quick Ratio1.5Cash flow > EarningsY
Price/Sales5.25-y EBITDA Growth Rate %0Current Ratio1.9Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %-2.9ROA % (ttm)17.6Higher Current Ratio y-yY
Dividend Yield %3.0Insider Buy (3m)0ROE % (ttm)56.8Less Shares Outstanding y-yN
Payout Ratio %63.0Shares Outstanding M6,795ROI % (ttm)33.6Gross Margin Increase y-yY

Gurus Latest Trades with RHHBY

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
RHHBYKen Fisher 2014-06-30 Reduce-0.07%$35.42 - $38.07
($36.82)
$ 36.58-1%Reduce -49.71%1,813,443
RHHBYKen Fisher 2014-03-31 Add0.07%$18.14 - $38.17
($29.75)
$ 36.5823%Add 99%1,803,070
RHHBYTweedy Browne 2013-06-30 Sold Out $28.92 - $32.98
($30.92)
$ 36.5818%Sold Out0
RHHBYKen Fisher 2013-03-31 Add0.12%$25.25 - $29.3
($27.74)
$ 36.5832%Add 634.57%897,861
RHHBYTweedy Browne 2012-09-30 Reduce-0.03%$20.95 - $24.07
($22.41)
$ 36.5863%Reduce -24.31%62,164
RHHBYVanguard Health Care Fund 2012-06-30 Add2.96%$19.47 - $23.14
($21.16)
$ 36.5873%Add 543.36%4,273,977
RHHBYKen Fisher 2012-06-30 Reduce-0.01%$19.47 - $23.14
($21.16)
$ 36.5873%Reduce -24.26%154,713
RHHBYKen Fisher 2012-03-31 Reduce-1.27%$21.55 - $22.17
($20.04)
$ 36.5882%Reduce -98.02%204,276
RHHBYTweedy Browne 2012-03-31 Reduce-0.04%$21.55 - $22.17
($20.04)
$ 36.5882%Reduce -22.19%82,130
RHHBYKen Fisher 2009-03-31 Add1.01%$13.37 - $18.53
($15.95)
$ 36.58129%Add 96.11%12,225,393
RHHBYVanguard Health Care Fund 2009-03-31 Reduce-0.2%$13.37 - $18.53
($15.95)
$ 36.58129%Reduce -52.1%429,320
RHHBYVanguard Health Care Fund 2008-12-31 Add2.01%$31.33 - $38.5
($35.55)
$ 36.583%Add 95.76%5,113,297
RHHBYPRIMECAP Management 2008-12-31 Sold Out -1.2%$31.33 - $38.5
($35.55)
$ 36.583%Sold Out0
RHHBYKen Fisher 2008-12-31 Reduce-1.15%$8.06 - $19.92
($17.52)
$ 36.58109%Reduce -56.79%6,233,841
RHHBYPRIMECAP Management 2008-09-30 Buy 1.2%$20.05 - $22.89
($21.5)
$ 36.5870%New holding, 4306500 sh.4,306,500
RHHBYKen Fisher 2008-06-30 Add1.14%$19.95 - $23.69
($21.4)
$ 36.5871%Add 223.59%7,046,449
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

RHHBY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
RHHBY Ken Fisher 2014-06-301,813,4430.030.14-49.71%
Premium Most recent portfolio changes are included for Premium Members only!


RHHBY: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Press Releases about RHHBY :

    Quarterly/Annual Reports about RHHBY:

      News about RHHBY:

      Articles On GuruFocus.com
      Tweedy Browne Global Reports its Top Five Picks of Q3 Oct 21 2014 
      Widely Held Guru Stocks Trading In Europe Sep 22 2014 
      Dodge & Cox Second Quarter 2014 Commentary Jul 23 2014 
      Tweedy Browne Global Reports Their Second Quarter Portfolio Jul 18 2014 
      Signature Select Canadian Fund's Top Holdings Jul 02 2014 
      The Tweedy Browne Global Value Fund's Top First Quarter Holdings Apr 22 2014 
      Most Popular International Stocks of Investment Gurus Mar 05 2014 
      John Rogers' Ariel Fund Comments on Roche Feb 28 2014 
      Ariel International Fund & Ariel Global Fund - Healthy Ideas Feb 28 2014 
      Tweedy Browne Global Value’s Top Five Year End Stocks Jan 24 2014 


      More From Other Websites
      Will Gilead (GILD) Miss Earnings on High Operating Costs? Oct 24 2014
      Biotech Stock Mailbag: Rockwell Medical, Oxigene, Prosensa, Sarepta Oct 24 2014
      Pharmacyclics Up on Label Expansion Efforts for Imbruvica Oct 22 2014
      NewLink-Roche Ink Deal for Oncology Candidate Development Oct 21 2014
      Can Valeant's Strong Q3 Entice Allergan? Oct 20 2014
      Small victories recorded in fight against Ebola Oct 20 2014
      Why NewLink Genetics (NLNK) Stock Is Soaring Today Oct 20 2014
      Stocks Open Quietly Mixed; Hasbro, NewLink, Akorn Rising Oct 20 2014
      NewLink Genetics Announces Exclusive Worldwide Licensing Agreement for Development of NLG919, an IDO... Oct 20 2014
      Pharmacyclics, Roche Ink Deal for Cancer Combo Therapy Oct 17 2014
      Roche Reports Strong Sales Results for 9 Months of 2014 Oct 17 2014
      Ohr Pharmaceutical's OHR-102 to Enter Phase III in 1H15 Oct 16 2014
      Pharmacyclics Enters Into Agreement with Roche to Evaluate IMBRUVICA® and GAZYVA® in Lymphoma and... Oct 16 2014
      Swiss drug maker Roche posts flat 9-month sales Oct 16 2014
      Swiss drug maker Roche posts flat 9-month sales Oct 16 2014
      F.D.A. Approves First 2 Drugs for Treatment of a Fatal Lung Disease Oct 15 2014
      FDA Approves Esbriet® (pirfenidone) for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) in the... Oct 15 2014
      FDA Approves Competing Lung Disease Drugs From Roche and Boehringer Oct 15 2014
      Roche (RHHBY) Progresses with Label Expansion of Lucentis Oct 09 2014
      FDA Grants Priority Review for Genentech’s Lucentis in Diabetic Retinopathy Oct 08 2014

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      Steve.dunfield@google
      ReplySteve.dunfield@google - 6 months ago
      Adjust for split?
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK